Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis
NCT00424294 · Pfizer · PHASE2 · terminated · last registry update 2014-09-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “See Detailed Description field” | – | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC5A2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-02-03Phase 3 first posted: Tanabe Pharma Corporation, Canagliflozin + Teneligliptin (NCT02354222)
- 2015-02-03Phase 3 first posted: Tanabe Pharma Corporation, Teneligliptin + Canagliflozin (NCT02354235)
- 2014-08-20Phase 3 first posted: Tanabe Pharma Corporation, Teneligliptin/Canagliflozin (NCT02220907)
- 2014-06-11Results posted on the registry: Tanabe Pharma Corporation, TA-7284 Low + TA-7284 High (NCT01512849)
- 2014-06-05Results posted on the registry: Tanabe Pharma Corporation, TA-7284 Low + TA-7284 High (NCT01413204)
- 2014-06-05Results posted on the registry: Tanabe Pharma Corporation, TA-7284-Low + TA-7284-Low-middle (NCT01022112)
- 2014-04-28Results posted on the registry: Tanabe Pharma Corporation, TA-7284-Low + TA-7284-High (NCT01387737)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision